Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 1.61% during midday trading on Thursday, reaching $463.40. 1,421,624 shares of the company traded hands. The firm has a market capitalization of $49.14 billion, a PE ratio of 46.49 and a beta of 1.62. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The stock has a 50 day moving average price of $460.30 and a 200 day moving average price of $451.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.82 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.93 earnings per share for the current fiscal year.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-director-sells-712500-00-in-stock/1611113.html.

A number of equities analysts recently issued reports on the stock. Leerink Swann reissued an “outperform” rating and issued a $573.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Raymond James Financial, Inc. reissued an “outperform” rating and issued a $547.00 price objective (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. BMO Capital Markets reissued a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Bank of America Corporation reissued a “buy” rating and issued a $593.00 price objective (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Sanford C. Bernstein downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $410.00 to $480.00 in a report on Monday, June 26th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $487.26.

Several institutional investors and hedge funds have recently made changes to their positions in REGN. Fieldpoint Private Securities LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $130,000. Sterling Investment Advisors Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares during the period. FNY Managed Accounts LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $140,000. FNY Partners Fund LP lifted its stake in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. Finally, Alpha Windward LLC lifted its stake in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the last quarter. Institutional investors and hedge funds own 67.95% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.